Sacconi, S, Antozzi, C, Cortes-Vicente, E, Pascuzzi, R, Utsugisawa, K, Vissing, J, Vu, T, Bloemers, J, Grimson, F, Tarancon, T, Bril, V. Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Skripuletz, T, Allen, J, Rinaldi, S, Lauria, G, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Stettner, M, Lewis, R, van Doorn, P. Efgartigimod in pretreated patients with CIDP and progressive/relapsing or persistent disease activity. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Vicente, EC, Pease, S, Imran, N, Gandhi, K, Ait-Tihuaty, M, Turkoz, I, Coteur, G, Gary, C, Choudhry, Z, Ramchandran, S, Vissing, J. Assessment of patient-reported outcomes from the phase 3 vivacity-MG3 study of nipocalimab in gMG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Villaverde, R, Gomez-Ballesteros, R, Reyes, V, Armangue, T, Querol, L, Gutierrez-Gutierrez, G, Sotoca, J, Ares, A, Salas, E, Abos, PD, Squaglia, A, Maurino, J, Cortes-Vicente, E. Herding-like behaviour in myasthenia gravis treatment decisions: exploring underlying mechanisms. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).